Impact of AIB1 expression on the prognosis of upper tract urothelial carcinoma after radical nephroureterectomy
Impact of AIB1 expression on the prognosis of upper tract urothelial carcinoma after radical nephroureterectomy
复制标题
AIB1表达对上尿路尿路上皮癌根治性肾输尿管切除术后预后的影响
DOI：
10.3233/cbm-182020
复制
发表时间：
2019-01-01
影响因子：
3.1
通讯作者：
Chen, Wei
中科院分区：
文献类型：
--
作者：
Huang, Yong;Cen, Junjie;Chen, Wei
背景：乳腺癌中扩增基因1(AIB1)是人类乳腺癌的候选癌基因，已被发现在多种类型的人类癌症中扩增和过表达。目的：探讨AIB1在上尿路癌中的作用。方法：采用免疫组织化学方法检测133例上尿路癌组织中AIB1的表达。总体而言，使用Kaplan-Meier方法评估癌症特异性和无复发生存率(OS、CS和RFS)。结果：AIB1的高表达与5年CS(80.6%vs.55.8%，p=0.008)和OS(78.1%vs.54.8%，p=0.006)的风险增加相关。多变量分析显示，AIB1表达升高是OS、CSS和RFS的独立预后预测因素。此外，PT、PN和肾积水与UTUC的肿瘤预后独立相关。结论：AIB1可作为UTUC临床预后的独立分子标志物。
BACKGROUND: Amplified in breast cancer 1 (AIB1) is a candidate oncogene in human breast cancer, which has been identified to be amplified and overexpressed in several types of other human cancers. Abnormalities of AIB1 and its clinical/prognostic significance, however, in upper tract urothelial carcinoma (UTUC) remain unclear.OBJECTIVE: To explore what role AIB1 plays in upper tract urothelial carcinoma.METHODS: The expression of AIB1 was analyzed using immunohistochemical staining in 133 UTUC patients. Overall, cancer specific and recurrence-free survival rates (OS, CSS, and RFS) were estimated using the Kaplan-Meier method. Multivariable COX regression models containing relevant clinicopathological variables addressed the prediction of postoperative outcome.RESULTS: High AIB1 expression was observed to be associated with increased hazard ratios for 5-year CSS (80.6% vs. 55.8%, p = 0.008) and OS (78.1% vs. 54.8%, p = 0.006). Multivariable analysis revealed that elevated AIB1 expression was an independent prognostic predictor of OS, CSS and RFS. Additionally, pT, pN and hydronephrosis were independently associated with oncologic outcome of UTUC. Three proposed nomograms were proposed to provide an individualized risk estimate of postoperative outcome in patients with UTUC.CONCLUSIONS: AIB1 can be used as an independent molecular marker for the prognosis of clinical outcomes of UTUC.